Source: Annual Congress 2011 - Innovative diagnostic methods for lung cancer
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
B. Schmidt, C. Kneip, A. Seegebarth, M. Fleischhacker, V. Liebenberg, D. Dietrich (Halle, Mainz, Berlin, Germany). SHOX2 DNA methylation is a promising biomarker for the diagnosis of lung cancer in plasma. Eur Respir J 2011; 38: Suppl. 55, 4505

Member's Comments

No comment yet.

Related content which might interest you: PTGER4, a promising novel DNA methylation marker for lung cancer measured in a clinical case control study using blood plasma Source: Annual Congress 2008 - Novel mechanisms and targets of molecular pulmonary pathology Year: 2008 DNA methylation and histone modifications of susceptibility in COPD and lung cancer Source: Annual Congress 2011 - Why is epigenetics important for lung disease? Year: 2011 RARβ2 methylation level in blood for lung cancer assessment Source: Annual Congress 2011 - Lung cancer: molecular pathology and functional genomics Year: 2011 Which gene expression signatures in pharmacogenomic strategies for lung cancer? Source: Annual Congress 2010 - Customised chemotherapy for lung cancer Year: 2010 Free plasmatic circulating DNA as prognostic and diagnostic lung cancer biomarker Source: Annual Congress 2008 - Novel trends in functional genomics and molecular pathology of neoplastic and non-neoplastic lung diseases Year: 2008 Early detection of lung cancer: role of biomarkers Source: Eur Respir J 2003; 21: 36S-44S Year: 2003 Hypermethylation pattern in genomic DNA samples derived from tumor and serum of resected non-small cell lung cancer patients Source: Eur Respir J 2004; 24: Suppl. 48, 674s Year: 2004 Identification of membrane-associated proteins as new candidate biomarkers of small-cell lung cancer Source: Annual Congress 2010 - The role of biomarkers in lung cancer Year: 2010 Clinicopathological significance and prognostic importance of circulating plasma DNA expression in advanced non-small cell lung cancer and its efficacy as a diagnostic tool Source: Annual Congress 2012 - New insights in the pathology of lung cancer Year: 2012 DNA methylation marker for NSCLC and adjacent normal lung tissue using NotI-MseI methylation chip Source: Eur Respir J 2007; 30: Suppl. 51, 132s Year: 2007 Circulating free DNA concentration is an independent prognostic biomarker in lung cancer Source: Eur Respir J 2015; 46: 1773-1780 Year: 2015 Plasma DNA level in predicting therapeutic efficacy in advanced nonsmall cell lung cancer Source: Eur Respir J 2010; 36: 885-892 Year: 2010 DNA methylation markers of surfactant proteins in lung cancer Source: Annual Congress 2007 - Novel mediators of cellular pathology Year: 2007 Recognition of aberrant promoter methylation for early diagnosis of lung cancer patients Source: Virtual Congress 2020 – Screening and early lung cancer Year: 2020 Can high levels of serum tumor markers be useful in predicting the histologic type of lung cancer? Source: Eur Respir J 2004; 24: Suppl. 48, 77s Year: 2004 Clinical evaluation of the plasma levels of hTERT and EGFR expression as markers for early detection of non-small cell lung cancer Source: Annual Congress 2009 - Basic science and lung cancer Year: 2009 DR-70, A promising biomarker for the detection of lung cancer> Source: Virtual Congress 2021 – Screening, diagnosis, management and prognosis of lung cancer Year: 2021 Dysplasia and aberrant methylation profiles in risk and lung cancer patients Source: Eur Respir J 2005; 26: Suppl. 49, 458s Year: 2005 The detection of quantitative serum p53 protein in lung cancer and its clinical value Source: Eur Respir J 2003; 22: Suppl. 45, 363s Year: 2003